RTP Mobile Logo

LIVE WEBINAR: Wednesday, February 9, 2022, 5:00 PM – 6:00 PM Eastern Time (ET)

Key Considerations in the Optimal Clinical Care of Patients with Small Cell Lung Cancer

A CME/MOC-Accredited Virtual Event

Register Now

Register for this complimentary event with the “Register Now” button above,
which will take you to our Zoom registration page.

Event Details

Join us on Wednesday, February 9th for this CME/MOC-accredited webinar
5:00 PM – 6:00 PM ET

Luis Paz-Ares, MD, PhD
Chair of the Medical Oncology Department at the Hospital Universitario 12 de Octubre
Associate Professor at the Universidad Complutense
Head of the Lung Cancer Unit at the National Oncology Research Center
Madrid, Spain

Jared Weiss, MD
Professor of Medicine
UNC School of Medicine
Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina

Neil Love, MD
Research To Practice
Miami, Florida

This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Genentech, a member of the Roche Group, G1 Therapeutics Inc and Jazz Pharmaceuticals Inc.


Wednesday, February 9, 2022
5:00 PM – 6:00 PM Eastern Time
Live CME/MOC-accredited webinar

Topics to Be Discussed

  • MODULE 1: Current Management of Newly Diagnosed Extensive-Stage Small Cell Lung Cancer (SCLC)
  • MODULE 2: Selection and Sequencing of Therapy for Patients with Progressive SCLC
  • MODULE 3: Recognition and Management of Adverse Events Associated with Available Treatments for SCLC

CE Information

Target Audience
This activity is intended for medical oncologists, hematology-oncology fellows, radiation oncologists and other allied healthcare professionals involved in the treatment of lung cancer.

Learning Objectives
Upon completion of this activity, participants should be able to

  • Formulate up-to-date management strategies for patients with small cell lung cancer (SCLC), considering the roles of local therapy, chemotherapy and immunotherapy.
  • Review long-term data supporting the use of atezolizumab or durvalumab in combination with platinum-based chemotherapy as first-line therapy for patients with extensive-stage SCLC, and consider how these regimens can be appropriately and safely integrated into clinical practice.
  • Consider the FDA approval of and available clinical trial findings with lurbinectedin for patients with SCLC who experience disease progression on or after platinum-containing therapy, and determine how to optimally integrate this agent into current treatment algorithms.
  • Compare and contrast the side effects associated with recently approved agents and strategies for the treatment of SCLC, and formulate a plan to minimize and manage these toxicities.
  • Recall the mechanism of action and recent FDA approval of the novel reversible CDK4/6 inhibitor trilaciclib, and consider the use of this agent to reduce chemotherapy-induced bone marrow suppression in patients with extensive-stage SCLC.
  • Assess ongoing clinical research evaluating novel agents and strategies under development for the management of SCLC, and counsel patients regarding the potential benefits of trial participation.

CE Credit
CME and ABIM MOC credit form links will be emailed to each participant within 5 days of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component and a short post-test, enables the participant to earn up to 1 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.

Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information. For those clinicians wishing to receive ABIM MOC credit for attending, you will receive an email after the event with instructions.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Dr Paz-AresAdvisory Committee: Amgen Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, GlaxoSmithKline, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, Lilly, Merck Serono, Merck Sharp & Dohme Corp, Mirati Therapeutics, Novartis, Pfizer Inc, PharmaMar, Roche Laboratories Inc, Sanofi Genzyme, Takeda Pharmaceutical Company Limited; Board of Directors: Altum Sequencing, GENOMICA; Contracted Research: Alkermes, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Daiichi Sankyo Inc, IO Biotech, Janssen Biotech Inc, Lilly, Merck Sharp & Dohme Corp, Novartis, Pfizer Inc, PharmaMar, Roche Laboratories Inc, Sanofi Genzyme, Takeda Pharmaceutical Company Limited, Tesaro, A GSK Company. Dr WeissConsulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Azitra, Boehringer Ingelheim Pharmaceuticals Inc, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Jazz Pharmaceuticals Inc, Lilly, Nanobiotix, Pfizer Inc, Regeneron Pharmaceuticals Inc, Saatchi & Saatchi Wellness, Sumitomo Dainippon Pharma Oncology Inc; Contracted Research: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Celgene Corporation, G1 Therapeutics Inc, Inspirna, Merck; Data and Safety Monitoring Board/Committee: BeiGene Ltd, EMD Serono Inc, Jounce Therapeutics; Ownership Interest: Achilles Therapeutics, Lyell, Nuvalent, Vesselon (warrants).

MODERATORDr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, Daiichi Sankyo Inc, Eisai Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Mersana Therapeutics Inc, Natera Inc, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Servier Pharmaceuticals LLC, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc and Zymeworks Inc.

Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Genentech, a member of the Roche Group, G1 Therapeutics Inc and Jazz Pharmaceuticals Inc.